CD274 and neoplasm: A 10-gene IFN-γ signature panel, and subsequently a 28-gene panel in patients with metastatic melanoma receiving anti-PD1 ICI was shown to correlate with improved response, PFS, and OS in patients across 9 tumor types receiving PD-L1 blockade [39, 40].